OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RAIB59

Rainbow Children's Medicare Ltd

Healthcare Facilities & ServicesVerified

Rainbow Children's Medicare Ltd maintains a strong liquidity position, with a current ratio of 5.46, indicating the company can easily cover its short-term liabilities with its short-term assets. However, the company's liquidity risk is assessed as medium, primarily due to a negative net cash position after subtracting total debt. The debt-to-equity ratio of 0.52 suggests a moderate level of leverage, with long-term debt amounting to INR 7.64 billion against total equity of INR 14.68 billion. In terms of profitability, the company demonstrates strong returns, with a return on equity (ROE) of 16.58% and a return on assets (ROA) of 10.24%. These figures are well above the industry median for Healthcare Facilities & Services, indicating superior operational efficiency and asset utilization. The operating margin, calculated as operating income of INR 3.52 billion on revenue of INR 15.16 billion, stands at 23.25%, further reinforcing the company's profitability. The company's revenue is primarily concentrated in its core pharmaceutical and healthcare services segments, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to regional economic or regulatory risks, though the exact geographic breakdown is not available in the current dataset. Looking ahead, the company is projected to maintain a stable growth trajectory, with analysts forecasting a mean price target of INR 1,561.33 and a median price target of INR 1,550.00. The mean recommendation of 1.67, with 4 strong-buy and 4 buy ratings, suggests a generally positive outlook from the investment community. The company's free cash flow of INR 2.07 billion and operating cash flow of INR 3.96 billion support its ability to fund operations and potentially invest in growth opportunities. The risk assessment indicates a low dilution potential, with no significant dilution sources identified in the available data. However, the company's capital expenditure of INR 1.46 billion in the latest period suggests ongoing investment in infrastructure or expansion. The risk of dilution remains low, with no near-term pressure expected, and no recent issuance or shelf registration disclosed in the data. Recent events and filings do not show any material changes in the company's operations or financial position. The company's financial performance remains consistent with its historical trends, and no significant regulatory or legal issues have been disclosed in the available data.

30-day price · RAIB+101.00 (+8.1%)
Low$1225.00High$1365.00Close$1355.00As of22 May, 00:00 UTC
Profile
CompanyRainbow Children's Medicare Ltd
TickerRAIB.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Rainbow Children's Medicare Ltd provides pharmaceutical products and healthcare services, primarily generating revenue through the sale of medicines and related healthcare solutions.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Rainbow Children's Medicare Ltd maintains a strong liquidity position, with a current ratio of 5.46, indicating the company can easily cover its short-term liabilities with its short-term assets. However, the company's liquidity risk is assessed as medium, primarily due to a negative net cash position after subtracting total debt. The debt-to-equity ratio of 0.52 suggests a moderate level of leverage, with long-term debt amounting to INR 7.64 billion against total equity of INR 14.68 billion. In terms of profitability, the company demonstrates strong returns, with a return on equity (ROE) of 16.58% and a return on assets (ROA) of 10.24%. These figures are well above the industry median for Healthcare Facilities & Services, indicating superior operational efficiency and asset utilization. The operating margin, calculated as operating income of INR 3.52 billion on revenue of INR 15.16 billion, stands at 23.25%, further reinforcing the company's profitability. The company's revenue is primarily concentrated in its core pharmaceutical and healthcare services segments, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to regional economic or regulatory risks, though the exact geographic breakdown is not available in the current dataset. Looking ahead, the company is projected to maintain a stable growth trajectory, with analysts forecasting a mean price target of INR 1,561.33 and a median price target of INR 1,550.00. The mean recommendation of 1.67, with 4 strong-buy and 4 buy ratings, suggests a generally positive outlook from the investment community. The company's free cash flow of INR 2.07 billion and operating cash flow of INR 3.96 billion support its ability to fund operations and potentially invest in growth opportunities. The risk assessment indicates a low dilution potential, with no significant dilution sources identified in the available data. However, the company's capital expenditure of INR 1.46 billion in the latest period suggests ongoing investment in infrastructure or expansion. The risk of dilution remains low, with no near-term pressure expected, and no recent issuance or shelf registration disclosed in the data. Recent events and filings do not show any material changes in the company's operations or financial position. The company's financial performance remains consistent with its historical trends, and no significant regulatory or legal issues have been disclosed in the available data.
Key takeaways
  • Rainbow Children's Medicare Ltd maintains a strong liquidity position with a current ratio of 5.46.
  • The company's ROE of 16.58% and ROA of 10.24% indicate strong profitability and efficient asset use.
  • Analysts project a positive outlook, with a mean price target of INR 1,561.33 and a median price target of INR 1,550.00.
  • The company's debt-to-equity ratio of 0.52 suggests moderate leverage, with no immediate dilution risk.
  • Free cash flow of INR 2.07 billion supports operational flexibility and potential for growth investments.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$15.16B
Gross profit$12.93B
Operating income$3.52B
Net income$2.43B
R&D
SG&A
D&A
SBC
Operating cash flow$3.96B
CapEx-$1.46B
Free cash flow$2.07B
Total assets$23.77B
Total liabilities$9.09B
Total equity$14.68B
Cash & equivalents
Long-term debt$7.64B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$14.68B
Net cash-$7.64B
Current ratio5.5
Debt/Equity0.5
ROA10.2%
ROE16.6%
Cash conversion1.6%
CapEx/Revenue-9.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricRAIBActivity
Op margin23.2%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin16.1%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin85.3%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-9.6%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity52.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target1,561.33 INR
Median price target1,550.00 INR
High price target1,812.00 INR
Low price target1,345.00 INR
Mean recommendation1.67 (1=strong buy, 5=strong sell)
Strong-buy count4.00
Buy count4.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate25.89 INR
Last actual EPS23.84 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 02:15 UTC#8cd1a4d9
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 03:36 UTCJob: 7649ec25